StoneX Group Inc. Invests $433,000 in Kenvue Inc. (NYSE:KVUE)

StoneX Group Inc. acquired a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 20,260 shares of the company's stock, valued at approximately $433,000.

Other institutional investors also recently bought and sold shares of the company. National Bank of Canada FI increased its position in Kenvue by 277.5% during the 4th quarter. National Bank of Canada FI now owns 1,215,553 shares of the company's stock worth $25,952,000 after purchasing an additional 893,557 shares during the period. Franklin Resources Inc. lifted its holdings in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after acquiring an additional 16,269,721 shares during the period. B. Metzler seel. Sohn & Co. AG boosted its position in shares of Kenvue by 17.6% during the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 131,477 shares of the company's stock worth $2,807,000 after purchasing an additional 19,693 shares in the last quarter. Skba Capital Management LLC grew its stake in shares of Kenvue by 6.4% during the 4th quarter. Skba Capital Management LLC now owns 601,330 shares of the company's stock worth $12,838,000 after purchasing an additional 36,070 shares during the period. Finally, O Shaughnessy Asset Management LLC increased its holdings in shares of Kenvue by 28.4% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 59,771 shares of the company's stock valued at $1,276,000 after purchasing an additional 13,203 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Down 5.5 %

NYSE KVUE traded down $1.29 during trading hours on Friday, hitting $22.33. The company had a trading volume of 17,763,957 shares, compared to its average volume of 16,812,043. The firm's 50 day moving average is $22.59 and its 200 day moving average is $22.46. The company has a market capitalization of $42.68 billion, a price-to-earnings ratio of 42.14, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on KVUE shares. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays boosted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Thursday, March 27th. Finally, Canaccord Genuity Group increased their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.